9th – 10th November 2017
Crowne Plaza, Newcastle, UK
Confirmed sessions include:
- Sport & exercise in addiction and recovery with personal reflections from Clarke Carlisle.
- End of life care for people with substance problems.
- The psychedelic renaissance in addiction treatment.
- Pathways to amphetamine type stimulant use.
NEW for 2017: The ADDICTION DEBATE
‘This Society believes it is appropriate to expand the concept of addiction to behaviours such as internet use’
With Professor Robert West & Professor Mark Griffiths
New for 2017, the SSA’s PhD Symposium will be held the day before our annual Conference, in the same venue.
The SSA’s symposium for PhD students is now in its ninth year. This event aims to bring together PhD students studying addiction-related topics so they can network, present their work in a low-key, supportive environment and share their ups and downs. It welcomes full and part-time students, studying in a range of disciplines including social sciences, laboratory sciences and health services research. The day includes presentations from students at various stages in the PhD process and some close to or who have recently submitted their thesis.
There is a social event in the evening of the PhD Symposium, and throughout the day there is plenty of opportunity to talk to other delegates.
For more information about this event please visit: www.addiction-ssa.org/symposium
GRAND is a Pfizer-supported independently reviewed competitive grants program awarding individual grants of up to $200,000 from a total fund in 2017 of $1 million to support projects which directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Of 486 applications received since 2008, 62 grants have been awarded.
Pfizer has called for Clinical research proposals that aim to increase the understanding of the mechanisms of tobacco and nicotine dependence and its treatment. The overall mission of the GRAND program is to advance the pharmacological treatment of tobacco and nicotine dependence.
Each proposal should fall into one of the following areas:
- Human laboratory (e.g., pharmacokinetics, pharmacodynamics, cravings, withdrawal);
- Pharmacotherapy of smoking cessation and relapse, and / or its interaction with behavioral support;
- Characterization of subtypes of smokers; suitability for appropriate interventions.
Research projects should aim to provide information that could directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Examples could include:
- Observational or interventional studies of pharmacotherapy
- Optimization of the use of currently available medication
- Effectiveness of pharmacotherapy in real-life settings
- Development or use of new medications for cessation or harm reduction
- Specifically designed pharmacotherapy in subtypes of tobacco/nicotine users
- Use of existing databases to inform the clinical use of pharmacotherapy
- Policy interventions to increase use of pharmacotherapy.
The intent of the program is to fund at least 6 awards of between $50,000 and $200,000 in value, totaling $1.2 million. The awards are open to all investigators and they would strongly encourage applications from junior investigators.
Applications will be formally assessed by, and only by, the GRAND Review Committee, an independent committee comprising internationally prominent researchers in the field. The final responsibility for selection of Awardees rests with the Co-Chairs of the Review Committee, John Hughes and Karl Fagerstrom. The whole process is completely independent of Pfizer, including the final selection of Awardees.
GRAND is open to all investigators from around the world holding an MD, a PhD, or equivalent.
Application deadline: July 3, 2017
To apply for the grant and for more information on the application process click here!